Specifically, regarding mitochondrial dysfunction, only the older adult cohort treated with GlyNAC significantly lowered 65% mitochondrial glucose oxidation (MGO), and upregulated 78% mitochondrial fatty-acid oxidation (MFO) towards levels not different from the young adult group
These medications work through different receptor mechanisms, have different pharmacokinetic profiles, and produce different physiological responses at every dose level
Likewise, endothelial cells are regulating mucosal immune homeostasis, acting as "gatekeepers", controlling leukocyte accumulation in the interstitial compartment
One very small human study did report that some participants with knee pain felt relief, but this is far from the large-scale, controlled evidence needed to prove it works
BPC-157 is not approved by the FDA or veterinary regulatory agencies for use in animals